CSIMarket



Dyne Therapeutics Inc   (DYN)
Other Ticker:  
 
 

DYN's Net Income Growth by Quarter and Year

Dyne Therapeutics Inc 's Net Income results by quarter and year




DYN Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -51.79 383.48 -296.00
III Quarter September - -42.58 -13.92 596.00
II Quarter June - -29.96 -95.00 -182.00
I Quarter March -35.58 -24.97 -133.00 -249.00
FY   -35.58 -149.30 141.56 -131.00



DYN Net Income first quarter 2022 Y/Y Growth Comment
Dyne Therapeutics Inc in the first quarter 2022 recorded net loss of $ -35.58 millions.

According to the results reported in the first quarter 2022, Dyne Therapeutics Inc achieved the best Net Income growth in Biotechnology & Pharmaceuticals industry. While Dyne Therapeutics Inc ' s Net Income no change of % ranks overall at the positon no. in the first quarter 2022.




DYN Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Dyne Therapeutics Inc 's first quarter 2022 Net Income $ -35.58 millions DYN's Income Statement
Dyne Therapeutics Inc 's first quarter 2021 Net Income $ -24.97 millions Quarterly DYN's Income Statement
New: More DYN's historic Net Income Growth >>


DYN Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Dyne Therapeutics Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DYN's I. Quarter Q/Q Net Income Comment
Although Dyne Therapeutics Inc in the I. Quarter 2022 admitted net loss of $ -35.58 millions, management mentioned, that current results are slight up side in contrast to the -51.79 millions in the forth quarter.

Within Biotechnology & Pharmaceuticals industry Dyne Therapeutics Inc achieved highest sequential Net Income growth. While Dyne Therapeutics Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


DYN's I. Quarter Q/Q Net Income Comment
Even if Dyne Therapeutics Inc in the I. Quarter 2022 revealed net loss of $ -35.58 millions, it should be said, that this show slight up side compare to the -51.79 millions in the forth quarter.

Within Biotechnology & Pharmaceuticals industry Dyne Therapeutics Inc achieved highest sequential Net Income growth. While Dyne Therapeutics Inc 's Net Income growth quarter on quarter, overall rank is .


Dyne Therapeutics Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Net Income 12 Months Ending $ -159.91 $ -149.29 $ 285.98 $ 314.64 $ 249.60
Y / Y Net Income Growth (TTM) - - - 337 % -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - -9.11 % 26.06 % 76.31 %
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Dyne Therapeutics Inc realized trailing twelve months net loss of $ -160 millions, in the Mar 31 2022, compare to Net Income of $ 250 millions a year ago.

Dyne Therapeutics Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Dyne Therapeutics Inc realized trailing twelve months net loss of $ -160 millions, in the Mar 31 2022, compare to Net Income of $ 250 millions a year ago.

Dyne Therapeutics Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
DYN's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for DYN's Competitors
Net Income Growth for Dyne Therapeutics Inc 's Suppliers
Net Income Growth for DYN's Customers

You may also want to know
DYN's Annual Growth Rates DYN's Profitability Ratios DYN's Asset Turnover Ratio DYN's Dividend Growth
DYN's Roe DYN's Valuation Ratios DYN's Financial Strength Ratios DYN's Dividend Payout Ratio
DYN's Roa DYN's Inventory Turnover Ratio DYN's Growth Rates DYN's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2022
Catalyst Pharmaceuticals Inc 72.79%$ 72.791 millions
Repligen Corp59.47%$ 59.470 millions
Conmed Corporation51.88%$ 51.876 millions
Becton Dickinson And Company51.33%$ 51.333 millions
Iqvia Holdings Inc 49.77%$ 49.770 millions
Charles River Laboratories International inc 48.94%$ 48.942 millions
Co diagnostics Inc 48.31%$ 48.305 millions
Phibro Animal Health Corp45.46%$ 45.457 millions
Abcellera Biologics Inc 43.81%$ 43.808 millions
Medpace Holdings Inc 41.58%$ 41.576 millions
Eli Lilly And Company40.40%$ 40.404 millions
Abbott Laboratories36.48%$ 36.475 millions
Merck and Co Inc 35.37%$ 35.374 millions
Bio techne Corp32.47%$ 32.470 millions
The Pennant Group Inc 26.83%$ 26.835 millions
Abbvie Inc 26.39%$ 26.385 millions
Tenet Healthcare Corp26.13%$ 26.126 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CREC's Profile

Stock Price

CREC's Financials

Business Description

Fundamentals

Charts & Quotes

CREC's News

Suppliers

CREC's Competitors

Customers & Markets

Economic Indicators

CREC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071